Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-11-20 DOI:10.1080/14796694.2024.2431479

Jialin Zhang, Jingyang Su, Cui Ni, Jinhua Lu

{"title":"Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis.","authors":"Jialin Zhang, Jingyang Su, Cui Ni, Jinhua Lu","doi":"10.1080/14796694.2024.2431479","DOIUrl":null,"url":null,"abstract":"Aim: We conducted a meta-analysis of published randomized controlled trials to compare the effectiveness and safety of eribulin versus paclitaxel for patients with breast cancer.Methods: We systematically searched multiple databases including Cochrane, PubMed, Medline, and Embase. The primary outcomes analyzed were overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), and adverse events (AEs). These outcomes were evaluated using RevMan5.3 software.Results: A total of 5 studies were included in the analysis. Compared to paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs not only extended the overall survival of patients but also improved the disease control rate (DCR) [risk ratio (RR) 0.98, (95% confidence intervals (CI): 0.70, 1.38), p = 0.92]. Hematological system diseases [RR 1.18 (95% CI: 1.07, 1.31), p = 0.002] were the most frequently observed adverse event with eribulin, while paclitaxel was more likely to cause nervous system lesion [RR 0.66 (95% CI: 0.54, 0.80), p < 0.0001].Conclusion: Compared with paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs can also prolong the PFS and OS of BC patients. Our recommendation is to use eribulin plus other chemotherapy drugs to treat advanced BC and to continuously monitor and manage the drug-related adverse events.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2431479","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We conducted a meta-analysis of published randomized controlled trials to compare the effectiveness and safety of eribulin versus paclitaxel for patients with breast cancer.

Methods: We systematically searched multiple databases including Cochrane, PubMed, Medline, and Embase. The primary outcomes analyzed were overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), and adverse events (AEs). These outcomes were evaluated using RevMan5.3 software.

Results: A total of 5 studies were included in the analysis. Compared to paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs not only extended the overall survival of patients but also improved the disease control rate (DCR) [risk ratio (RR) 0.98, (95% confidence intervals (CI): 0.70, 1.38), p = 0.92]. Hematological system diseases [RR 1.18 (95% CI: 1.07, 1.31), p = 0.002] were the most frequently observed adverse event with eribulin, while paclitaxel was more likely to cause nervous system lesion [RR 0.66 (95% CI: 0.54, 0.80), p < 0.0001].

Conclusion: Compared with paclitaxel plus other chemotherapy drugs, eribulin plus other chemotherapy drugs can also prolong the PFS and OS of BC patients. Our recommendation is to use eribulin plus other chemotherapy drugs to treat advanced BC and to continuously monitor and manage the drug-related adverse events.

查看原文本刊更多论文

艾瑞布林与紫杉醇在乳腺癌中的疗效和安全性比较：系统综述和荟萃分析。

目的：我们对已发表的随机对照试验进行了荟萃分析，以比较艾瑞布林与紫杉醇治疗乳腺癌患者的有效性和安全性：我们系统地检索了多个数据库，包括 Cochrane、PubMed、Medline 和 Embase。分析的主要结果包括总生存期（OS）、完全应答（CR）、部分应答（PR）、疾病稳定（SD）和不良事件（AEs）。这些结果使用RevMan5.3软件进行评估：共有5项研究纳入分析。与紫杉醇联合其他化疗药物相比，艾瑞布林联合其他化疗药物不仅延长了患者的总生存期，还提高了疾病控制率（DCR）[风险比（RR）0.98，（95%置信区间（CI）：0.70，1.38），P = 0.92]。血液系统疾病[RR 1.18 (95% CI: 1.07, 1.31)，P = 0.002]是艾瑞布林最常见的不良反应，而紫杉醇更容易引起神经系统病变[RR 0.66 (95% CI: 0.54, 0.80)，P 结论：与紫杉醇联合其他药物相比，艾瑞布林更容易引起神经系统病变：与紫杉醇联合其他化疗药物相比，艾瑞布林联合其他化疗药物也能延长BC患者的PFS和OS。我们建议使用艾瑞布林联合其他化疗药物治疗晚期BC，并持续监测和管理与药物相关的不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.